Personalized Treatments Hold Promise for Lymphoma Patients
As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.
As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.
Using the 'Pathway' Approach to Shorten the Time Between Cancer Diagnosis and Treatment
November 16th 2022In this episode of Tuning In to the C-Suite, Briana Contreras, editor with Managed Healthcare Executive spoke with Dr. Yuri Fesko, oncologist and vice president of Medical Affairs at Quest Diagnostics. In the conversation, Dr. Fesko addressed the ongoing issue of long gaps of times between receiving a diagnosis for a type of cancer and finally getting the treatment for it. Dr. Fesko shared the benefits a number of sectors receive when treating patients sooner and the steps to get there.
Listen
FDA Approves First BTK Inhibitor as First-Line Therapy for Mantle Cell Lymphoma
January 27th 2025The drug received accelerated approval in October 2017 as monotherapy for adults with MCL who have received at least one prior treatment. The FDA simultaneously converted the conditional approval to full approval for this indication.
Read More
